In overweight subjects with normal liver structure, visfatin immunostaining was weak to moderate (Fig. 3B) while, in hepatic steatosis, immunoreactivity of visfatin was minimal or negative (Fig. 3C). This evidence concerns the gene NAMPT and fatty liver disease.